Adjustable optical power intraocular lenses

Information

  • Patent Grant
  • 11266496
  • Patent Number
    11,266,496
  • Date Filed
    Thursday, June 7, 2018
    5 years ago
  • Date Issued
    Tuesday, March 8, 2022
    2 years ago
Abstract
The present technology is directed to an adjustable power intraocular lens comprising a container, an optical fluid in the container, and a transport substance in solution with the optical fluid. The container has an optical component and a peripheral component extending around at least a portion of the optical component. The optical component has an anterior optical element, a posterior optical element, and a fluid chamber having a chamber volume between the anterior optical element and the posterior optical element. The transport substance is configured to pass through the container. The adjustable power intraocular lens further comprises volume control elements in the container. The volume control elements are configured to be activated by a non-invasive energy and upon activation release the transport substance into the optical fluid to decrease the chamber volume and/or absorb the transport substance from the optical fluid to increase the chamber volume.
Description

Intraocular lenses (IOLs) are implantable optical devices for treating cataracts or myopia. IOLs typically replace native crystalline lenses that are cloudy or otherwise discolored due to cataracts. An IOL is surgically implanted by removing the native crystalline lens and then inserting an IOL into the native lens capsule. The World Health Organization estimates that 20 million IOLs were implanted worldwide in 2010 and predicts that 30 million IOLs will be implanted annually by 2020.


BACKGROUND

Many current IOLs have a single optical power that is set by the manufacturer. As a result, conventional single-power IOLs have a fixed optical power. This requires practitioners to determine the optical power of single-power IOLs before implantation. The optical power of an IOL, however, may not be correct after implantation because the IOL may not fit properly in the native lens capsule or the eye may change over time. If the optical power of an implanted single-power IOL is not correct, the IOL will need to be replaced with another IOL having a suitable optical power via another surgical procedure. This not only increases the cost of healthcare, but it is also inconvenient for the patients and subject to the normal complications of optical surgical procedures.





BRIEF DESCRIPTION OF THE DRAWINGS

Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily drawn to scale. Instead, emphasis is placed on illustrating clearly the principles of the present technology. Furthermore, components can be shown as transparent in certain views for clarity of illustration only and not to indicate that the component is necessarily transparent. Components may also be shown schematically.



FIG. 1 is a cross-sectional view of an adjustable power intraocular lens in accordance with the present technology.



FIGS. 2 and 3 are cross-sectional views of the operation of first and second volume control elements, respectively, used in adjustable power intraocular lenses in accordance with the present technology.



FIG. 4 is a cross-sectional view of an adjustable power intraocular lens in accordance with the present technology.



FIG. 5 is a cross-sectional view of an adjustable power intraocular lens in accordance with the present technology.



FIG. 6 is a cross-sectional view of an adjustable power intraocular lens in accordance with the present technology.



FIG. 7 is a plan view of an adjustable power intraocular lens in accordance with the present technology.



FIG. 8A is an isometric view and FIG. 8B is a cross-sectional view taken along section A-A of FIG. 8A of an adjustable power intraocular lens in accordance with the present technology.



FIG. 9A is an isometric view, FIG. 9B is a bottom plan view, and FIG. 9C is a cross-sectional view taken along cross-section A-A of FIG. 9B that illustrate a modular APIOL in accordance with the present technology.



FIG. 10A is a bottom isometric view of a fixed lens, and FIG. 10B is a cross-sectional view taken along section B-B of FIG. 10A.





OVERVIEW

Several embodiments of adjustable power intraocular lenses (APIOLs) in accordance with the present technology are described below with reference to FIGS. 1-8. The APIOLs described below are capable of changing the optical power in situ using a non-invasive activation. Although several examples of APIOLs are disclosed with respect to single-power devices, the concept can be applied to accommodating intraocular lenses as well as noted below.


The disclosed APIOLs provide the ability to selectively change the optical power in situ to adapt the APIOLs to the specific power required by the patient after implantation without removing and/or replacing the APIOLs. For example, several embodiments of APIOLs in accordance with the present technology include first volume control elements that release or expel a transport substance and/or second volume control elements that absorb or otherwise attract and retain a transport substance. The first volume control elements can be shrinking elements or release elements configured to release the transport substance upon non-invasive activation, such as an energy modality that selectively reacts with the first volume control elements. Conversely, the second volume control elements can be swelling elements configured to absorb or otherwise attract and retain the transport substance upon non-invasive activation. In operation, the shrinking elements can be activated to release the transport substance from the APIOL to reduce the optical power, or conversely the swelling elements can be activated to absorb the transport substance to increase the optical power.


APIOLs in accordance with present technology can include a container, an optical fluid in the container, and volume control elements in the container. The container can comprise a peripheral component and an optical component. The optical component, for example, can include an anterior optical element and a posterior optical element. The optical elements may be hydrophilic or hydrophobic. The container can comprise a water permeable material. One suitable water permeable material for the container comprises:

    • a—a hydrophilic acrylic copolymer;
    • b—Benz 25 UVX™ material manufactured by Benz Research and Development of Sarasota, Fla.; and
    • c—CI18, CI21, or CI26 produced by Contamac Ltd. of the UK


      Suitable hydrophilic acrylics include, but are not limited to, 2-Hydroxyethyl methacrylate (HEMA). Suitable hydrophobic acrylics include, but are not limited to, 2-Ethoxyethyl methacrylate (EOEMA), polymethyl methacrylate (PMMA), Butyl acrylate, Hexyl acrylate and Hexafluoroisopropyl acrylate. The acrylic, for example, can comprise a cross linker. In some embodiments, the acrylic comprises a cross-linked acrylic polymer. The hydrophilic or hydrophobic polymers may be copolymers of the above.


The internal optical fluid filling the container can comprise an oil. For example, the oil can have a refractive index greater than that of the aqueous humor. The oil can be capable of holding a saturation volume of water in solution at body temperatures of a human eye. The transport substance can be water.


The volume control elements can include first volume control elements configured to release a transport substance into the optical fluid in the container and/or second volume control elements configured to absorb a transport substance from the optical fluid. The first volume control elements can be shrinking elements that, when activated, release the transport substance into the optical fluid and thereby increase the volume of the transport substance in the fluid chamber. This causes the transport substance concentration within the container to exceed the saturation point such the transport substance is transported out of the container to the aqueous humor by diffusion. The reduction in the transport substance reduces the volume of matter in the container, which in turn reduces the optical power of the optical component. The second volume control elements can be swelling elements that, when activated, absorb the transport substance from the optical fluid. This too causes an imbalance of the transport substance within the container such that additional transport substance is transported from the aqueous humor into the container via diffusion. The increase in the transport substance increases the volume of matter in the container, which in turn increase the optical power of the optical component.


The first volume control elements, or shrinking elements, can include a first hydrophobic casing containing a volume of the transport substance. For example, the transport substance can be water and the first hydrophobic casing can be wax or a liposome (e.g., a uni-laminar liposome). In one example, the first volume control elements can be wax closed-cell foams containing water.


The second volume control elements, or swelling elements, can include one or more hydrophilic elements surrounded by a second hydrophobic casing. The hydrophilic elements can include a hydrogel such as acrylic polymers. The second hydrophobic casing can include parylene and/or a hydrophobic acrylic.


The first and/or second volume control elements can be fixed to the container. In other embodiments, the first and/or second volume control elements can be suspended in the optical fluid.


The optical component of APIOLs in accordance with the present technology can be a fluid lens comprising the optical fluid (e.g., oil) bounded by the anterior optical element and the posterior optical element. The peripheral component can surround the optical component such that the optical component is a central portion of the container. In some embodiments, one or both of the anterior and posterior optical elements may have an optical power (i.e., a defined curvature in a relaxed unbiased state) such that the optical component has an optical power in a relaxed state. In other embodiments, the anterior and/or posterior optical elements may be flat membranes that have no optical power in a relaxed unbiased state such that the optical component has no power in the relaxed state. The total volume of the optical fluid, transport substance and first and/or second volume control elements within the container can change the curvature, and thus the optical power, of the optical component. More specifically, the optical power increases when the volume of matter within the container increases, or conversely the optical power decreases when the volume of matter within the container decreases.


The volume of matter within the container is controlled by selectively activating the first volume control elements or the second volume control elements. The first or second volume control elements can be activated by disrupting all or a portion of the hydrophobic casings of the volume control elements. For example, in several embodiments the volume control elements are activated by exposing the volume control elements to a non-invasive activation energy that selectively disrupts either the first hydrophobic casings of the first volume control elements or the second hydrophobic casings of the second volume control elements. The non-invasive activation energy can include laser energy (e.g., light), ultrasound, electrical energy (e.g., radio frequency), and/or infrared.


DETAILED DESCRIPTION


FIG. 1 is a cross-sectional view schematically illustrating an APIOL 100 having a peripheral component 110 and an optical component 120. The peripheral component 110 and the optical component 120 together can define a container, or just the peripheral component can define the container. The peripheral component 110 can be an annular outer compartment that completely surrounds the optical component 120, or the peripheral component 110 can be discrete outer segments that extend around only a portion of the optical component 120. The peripheral component 110 can have interior volume 112 that is in fluid communication with the optical component 120. In other embodiments, however, the interior volume 112 of the peripheral component 110 can be fluidically isolated from the interior of the optical component 120. The peripheral component 110 can be stiffer than the optical component 120 such that changes in volume occur to a greater in the optical component 120 than in the peripheral component 110.


The optical component 120 can have an anterior optical element 122 coupled to an anterior portion of the peripheral component 110, a posterior optical element 124 coupled to a posterior portion of the peripheral component 110, and a fluid chamber 126 between the anterior optical element 122 and the posterior optical element 124. The anterior optical element 122 can be a first membrane, and the posterior optical element 124 can be a second membrane. The first and second membranes can have an optical power (e.g., have a set or minimum curvature) or they can have no optical power in a relaxed, unbiased state (e.g., horizontal in FIG. 1). The fluid chamber 126 can be filled with an optical fluid 128 such that the anterior optical element 122, the posterior optical element 124 and the optical fluid define a fluid lens 130. In operation the optical fluid 128 can fill both the peripheral component 110 and the fluid chamber 126 to impart the desired curvature to the anterior optical element 122 and/or the posterior optical element 124 to provide the desired optical power to the optical component 120. The optical component 120 can have a single power or it can be an accommodating fluid lens in which the optical power changes in response to movement of the muscles of the native eye.


The APIOL 100 can further include first volume control elements 140 and/or second volume control elements 160. The first volume control elements 140 can be shrinking elements or release elements configured to disgorge or otherwise release a transport substance using a first non-invasive activation modality. Conversely, the second volume control elements 160 can be swelling elements configured to absorb or otherwise attract and retain a substance using a second non-invasive activation modality. The first and second non-invasive activation modalities can be one or more types of energy, such as laser radiation, ultrasonic energy, radio frequency (RF) energy or infrared radiation, that selectively activates one or both of the first and second volume control elements 140 and 160. In several embodiments, the first non-invasive activation modality activates only the first volume control elements 140 and the second non-invasive activation modality activates only the second volume control elements 160 such that the first and second volume control elements 140 and 160 can be activated independently of each other. For example, the first volume control elements 140 can be activated by one type of energy (e.g., laser energy), while the second volume control elements 160 can be activated by a different type of energy (e.g., RF energy). In a different example, the first and second volume control elements 140 and 160 can be activated by a common type of energy at different wavelengths or frequencies. In this example the first volume control elements 140 can be activated by a type of energy at a first wavelength or frequency (e.g., laser energy in a first bandwidth) and the second volume control elements 160 can be activated by the same type of energy at a second wavelength or frequency (e.g., laser energy in a second bandwidth). The second bandwidth is sufficiently different than the first bandwidth to avoid joint activation of the first and second volume control elements. In other embodiments, a single non-invasive activation modality can activate both the first volume control elements 140 and the second volume control elements 160. Upon activation, the first and second volume control elements 140 and 160 can become first and second activated elements 142 and 162, respectively.


The optical fluid 128 and the transport substance (not shown in FIG. 1) are selected to maintain a desired equilibrium within the fluid chamber 126 with respect to the aqueous humor of the native eye. The transport substance is selected to transport through the walls of the peripheral component 110, the anterior optical element 122, and/or the posterior optical element 124 via osmosis to maintain the desired equilibrium between the optical fluid 128 and the transport substance within the fluid chamber 126. In several embodiments, the optical fluid 128 is an oil that can sustain a solubilized water content of greater than a few percent and the transport substance is water. As a result, the first volume control elements 140 (e.g., shrinking elements) provide a water source within the APIOL 100, whereas the second volume control elements 160 (e.g., swelling elements) provide a sink for water. As the internal volume is a changed by activating either the first volume control elements 140 elements or the second volume control elements 160, the volume of the matter in the fluid chamber 126 changes and thereby adjusts the power of the optical component 120 in situ. In general, when the internal volume of matter in the fluid chamber 126 increases the optical power increases, and conversely when the internal volume of matter in the fluid chamber 126 decreases the optical power decreases.



FIG. 2 schematically illustrates the operation of the first volume control elements 140, and more specifically releasing or expelling the transport substance (e.g., water) from the first volume control elements 140 to reduce the optical power of the optical component 120. In this aspect of the present technology, an energy source 170 produces a non-invasive activation energy 172 that interacts with the first volume control elements 140 such that the first volume control elements 140 release or otherwise expel the transport substance. As the transport substance is released from the first volume control elements 140, the transport substance over-saturates the internal fluid or optical fluid 128 within the APIOL 100. The excess transport substance passes through the wall of the peripheral component 110 and/or the optical elements 122, 124 of the optical component 120 into the surrounding aqueous humor. The internal volume of the APIOL 100 is therefore reduced by the volume of transport substance that transports out of the APIOL 100. Since the peripheral component 110 of the APIOL 100 is structurally stiffer than the optical component 120, the volume of the optical component 120 changes more than that of the peripheral component 110. The decrease in volume of the optical component 120 decreases the optical power of the optical component 120.



FIG. 3 schematically illustrates the operation of the second volume control elements 160, and more specifically absorbing or otherwise collecting the transport substance (e.g., water) in and/or on the second volume control elements 160 to increase the optical power of the optical component 120. In a specific example of the present technology, the optical power of the APIOL 100 increases by the sequestration of water into the second volume control elements 160. More specifically, the transport substance is absorbed into the second volume control elements 160 from the optical fluid, and the second volume control elements 160 swell to occupy more volume. The transport substance removed from the optical fluid is replaced by the same type of substance from the aqueous humor which passes through the peripheral component 110 and/or the optical component 120 from the surrounding aqueous humor into the optical fluid. This brings the chemistry of the optical fluid back to its equilibrium level (e.g., water:oil equilibrium ratio). The internal volume of the APIOL 100 is therefore increased by the volume of water which has been absorbed into the second volume control elements 160 within the APIOL 100. Since the peripheral component 110 of the APIOL 100 is structurally stiffer than the optical component 120, the volume of the optical component 120 increases and thereby increases the optical power of the optical component 120.



FIG. 4 is a cross-sectional view illustrating aspects of the optical component 120 in greater detail. The anterior optical element 122 and the posterior optical element 124 can define a container or structural portion of the APIOL 100. As illustrated, both membranes are thin and flat in a relaxed unbiased state (e.g., plate-like) and provide no optical power to the optical component 120 in this state. As the internal volume of the APIOL 100 increases, the membranes flex into roughly spherical curvatures. The high refractive index optical fluid 128 between the membranes, in combination with the optical elements 122 and 124, thereby forms the fluid lens 130 which has an optical power. The optical power of the fluid lens 130 increases as the volume of the optical fluid 128 in the fluid chamber 126 increases. In other embodiments (not shown), one or both the anterior optical element 122 and the posterior optical element 124 may have a curvature in a relaxed unbiased state such that they comprise an optical power. In still other embodiments, one of the anterior optical element 122 or posterior optical element 124 may be stiffer and or thicker than the other (not shown).



FIG. 5 illustrates an APIOL 500 in accordance with the present technology. The APIOL 500 is similar to the APIOL 100 described above, and like reference numbers refer to like components. The APIOL 500 is different than the APIOL 100 in that the peripheral component 110 and the optical component 120 of the APIOL 500 are fluidically isolated from each other by a barrier 510. The barrier 510, for example, can be a hydrophilic membrane. In such an embodiment, the barrier 510 constrains debris (“D”) associated with the activation of the first and/or second volume control elements 140, 160 from entering the fluid chamber 126 of the optical component 120. In some such embodiments, the membrane 510 may be continuous between the peripheral component 110 and the optical component 120, as illustrated in FIG. 5. Whereas in other embodiments the membrane 510 may contain channels or large pores 512 (shown in dotted line) which prevent or otherwise inhibit the debris D from passing into the optical component 120 while allowing the optical fluid 128 to pass to/from the fluid chamber 126. This embodiment is expected to be useful for providing an adjustable accommodating fluid lens in which the optical component 120 increases/decreases optical power as the native eye acts upon the peripheral component 110 to pump fluid into or withdraw fluid out to the fluid chamber 126 (see, e.g., International Application No. [Insert 120974.8012WO00], which is incorporated herein by reference).



FIG. 6 is a cross-sectional view illustrating an APIOL 600 in accordance with the present technology in which the optical component 120 is surrounded by a deformable barrier 610. The APIOL 600 is similar to the APIOLs 100 and 500 described above, and like reference numbers refer to like components. The fluid in the peripheral component 110, which includes the first and second volume control elements 140, 160, acts on the deformable barrier 610. In some embodiments, the deformable barrier 610 is bellows. In operation, the optical fluid 128 may have a more standard low solubility for water, and vacuoles of water released from the first volume control elements 140 diffuse to the outer surfaces of the peripheral component 110 that communicate with the aqueous humor.



FIG. 7 is a plan view of an APIOL 700 in accordance with the present technology in which like reference numbers refer to like components with respect to FIGS. 1-6. The APIOL 700 has a peripheral component 710 and the optical component 120 in the center of the peripheral component 710. The peripheral component 710 has a first compartment 714 containing a fluid and the first volume control elements 140, and the peripheral component 710 has a second compartment 716 containing a fluid and the second volume control elements 160. The APIOL 700 accordingly differs from the APIOLs 100, 500 and 600 in that the first volume control elements 140 are isolated from the second volume control elements 160 in the first and second compartments 714 and 716, respectively.



FIG. 8A is an isometric view and FIG. 8B is a cross-sectional view taken along section A-A of FIG. 8A of an APIOL 800 in accordance with the present technology. The APIOL 800 also isolates the first volume control elements 140 from the second volume control elements 160, but the APIOL 800 uses multiple compartments. More specifically, the APIOL 800 has a peripheral component 810 that completely surrounds the optical component 120, and the peripheral component 810 has a plurality of first compartments 814 configured to contain separate volumes of the first volume control elements 140 and a plurality of second compartments 816 configured to contain separate volumes of the second volume control elements 160. Each of the APIOLs 700 and 800 can have a connecting barrier between the compartments containing the volume control elements and the optical component 120. In such embodiments, deformation of the connecting barrier driven by activation of the volume control elements 140, 160 adjusts the peripheral volume of the optical component 120 of the APIOLs 700 and 800.


The first volume control elements 140 can have a thin outer wall and a volume of the transport substance within the thin outer wall. For example, the first volume control elements 140 can have a thin wax shell and a small volume of water encased within the shell. In other embodiments, the first volume control elements 140 can have water encased by a liposome shell, such as a uni-laminar liposome shell having of a bilayer lipid outer membrane. In other embodiments, the first volume control elements 140 can be a closed-cell wax foam with water in the voids of the closed-cell foam.


The second volume control elements 160 can comprise of an outer surface of hydrophobic material encasing either a hydrophilic material or a material which can diffuse or otherwise pass through the optical fluid 128 and/or some portion of the peripheral wall of the APIOL. For example, the second volume control elements 160 described herein can include a small volume of a dehydrated hydrogel encased in a thin layer of wax, a parylene coating, or a layer of an amphiphilic material such that the hydrophilic head groups are presented as the outer surface of the hydrogel and the hydrophobic tail groups are presented outwardly to the environment forming a micelle. The second volume control elements 160 can also be a closed-cell wax foam wherein the voids within the foam contain hydrogel.


The volume control elements 140, 160 described above can be activated by controllably disrupting the shells or outer coating layers thereby allowing a controlled amount of the contained material to access the local environment. Such energy may be one or any combination of laser energy, ultrasound, electrical energy including RF, and infrared energy. In some embodiments, the disruption is accomplished by the delivery of laser energy to the volume control elements. In some embodiments, the first volume control elements 140 and the second volume control elements 160 are activated by different wavelengths of laser energy or different frequencies of ultrasonic or electrical energies. For example, a first wavelength of laser energy is used to activate the first volume control elements 140, while a second different wavelength of laser energy is used to activate the second volume control elements 160. Such selectivity may be built into the volume control elements by controlling the absorbance of the coating material and or the size of the volume control element. In alternative embodiments, the first and second volume control elements 140, 160 may be compartmentalized such that they can be addressed separately as described above with reference to FIGS. 7, 8A and 8B.



FIG. 9A is an isometric view, FIG. 9B is a bottom plan view, and FIG. 9C is a cross-sectional view taken along cross-section A-A of FIG. 9B that illustrate a modular APIOL 900 in accordance with the present technology. Referring to FIGS. 9A and 9B, the APIOL 900 has an accommodation structure 910, a fixed lens 930, first volume control elements 140, and second volume control elements 160. Referring to FIG. 9C, the accommodating structure 910, for example, can have a first component 911 defining an anterior portion and a second component 912 defining a posterior portion. The first and second components 911 and 912 are assembled to form an outer fluid reservoir 914, a channel 916, and an inner fluid chamber 918 in fluid communication with each other. The outer fluid reservoir 914, channel 916 and inner fluid chamber 918 are filled with an optical fluid and transport substance in solution, which flow between the outer fluid reservoir 914 and the inner chamber 918 via the channel 916.


The accommodating structure 910 can have an accommodating optical element 920 (e.g., an accommodating fluid lens) having a first optical component 921 defining an anterior side of the inner fluid chamber 918 and a second optical component 922 defining a posterior side of the inner fluid chamber 918. The first and second optical components 921 and 922 can be flexible membranes that do not have an optical power, or in other embodiments one or both of the first and second components 921 and 922 can be flexible lenses that have an optical power. In operation, fluid flows between the outer fluid reservoir 914 and the inner chamber 918 in response to the movement of the ciliary muscles of the native eye. For example, when the ciliary muscles relax, the capsular bag pushes against the outer fluid reservoir 914, which in turn causes fluid to flow into the inner chamber 918 and deflect the first optical component 921 anteriorly. This increases the thickness of the accommodating optical element 920. Conversely, when the ciliary muscles contract, the capsular bag is pulled radially outward such that the force exerted against the outer fluid reservoir 914 decreases allowing the higher-pressure fluid in the inner chamber 918 to flow into the outer fluid reservoir 914. This decreases the thickness along the optical axis (e.g., curvature) of the accommodating optical element 920.


The APIOL 900 includes flow-through features 950 that enhance the rate and ease with which Ophthalmic Viscosurgical Devices (OVDs) used during the implantation of AIOLs can be removed from the natural lens capsule. The APIOL 900 can have three outer flow-through features 950. The outer flow-through features 950 can be detents, such as a recess, distributed circumferentially along the perimeter of the outer fluid reservoir 914. In the illustrated embodiment, the flow-through features 950 are formed in regions of the first and second components 911 and 912. Although three outer flow-through features 950 are illustrated, other embodiments may comprise less or more than illustrated. The outer flow-through features 950 may additionally constrain rotation of the APIOL 900 in the eye.


The APIOL 900 additionally comprises a fixed lens assembly 930. The fixed lens assembly 930 illustrated in FIG. 9C includes an optical portion 932, a skirt 934 extending from the optical portion 932, and passages 936. The optical portion 932 has a fixed power which may comprise an asymmetrically powered lens or other lens as explained herein, and the passages 936 are holes, slots, orifices, etc., that pass through the skirt 934 and extend into a perimeter region but not the optical portion 932.


Referring to FIG. 9C, the fixed lens assembly 930 has an engagement feature 938, such as an annular groove, that extends around the skirt 934, and the first component 911 of the accommodating structure 910 has a thickened region 939, such as an annular protrusion (e.g., a ledge) that extends radially inwardly. The fixed lens assembly 930 can be attached to the accommodating structure 910 by engaging the continuous thickened region 939 of the first component 910 with the engagement feature 938 of the fixed lens assembly 930. In other embodiments (not shown), the thickened region 939 and the engagement feature 938 may be discontinuous features (e.g., segmented or other recesses or protrusions that extend around less than the full circumference of the fixed lens assembly 930 and the accommodating structure 910). Such a discontinuous thickened region 939 and engagement feature 938 are desirable to maintain a particular radial alignment between the fixed lens assembly 930 and the accommodating structure 910, such as when the fixed lens assembly 930 comprises a toric lens or other asymmetrical lens. Alternatively, the groove may be in the fixed lens assembly 930 and the protrusion on the accommodating structure 910.


The fixed lens assembly 930 can be implanted after the accommodating portion 910 has been implanted. This is expected to be advantageous because the accommodating portion 910 can be implanted and then a fixed lens assembly 930 with the desired power can be selected and implanted later based on the actual post-implant optical power of the accommodating portion 910. The fixed lens assembly 930 can also be removed after being attached to the accommodating structure 910. This is advantageous if the fixed lens assembly 930 that was initially implanted is not correct or was damaged while being inserted into the accommodating structure 910.


The APIOL 900 can further include a square-shaped annular region 951 that inhibits cell migration from the periphery of the patient's capsule to the optical part of APIOL 900 (shown in FIG. 9C at the posterior most region of the lens). Such cell migration could cause post-surgery opacification of the optical system.


Referring to FIGS. 9B and 9C, the APIOL 900 includes the first and second volume control elements 140 and 160 in the outer fluid reservoir 914. As a result, when the first or second volume control elements 140 or 160 are activated, the volume of matter in the outer fluid reservoir 914 decreases or increases, respectively, as described above. The change in volume of matter in the outer fluid reservoir 914 accordingly changes the volume in the accommodating optical element 920, which in turn adjusts the power of the APIOL 900 as described above. This is expected to be useful even in the APIOL 900 that has a removable fixed lens assembly 930. For example, even though the fixed lens assembly 930 can be implanted after the accommodating structure 910 has been implanted or removed if not appropriate, activating the first or second volume control elements 140 or 160 can be used to further adjust the optical power of the APIOL 900 if needed.



FIG. 10A is a bottom isometric view of a fixed lens 1030, and FIG. 10B is a cross-sectional view taken along section B-B of FIG. 10A. The fixed lens 1030 is similar to the fixed lens 930 used in the modular accommodating APIOL 900 described above in FIGS. 9A-9C. The fixed lens 1030, however, includes the first and second volume control elements 140 and 160 either in lieu of or in addition to having the volume control elements 140 and/or 160 in the container. The fixed lens 1030 is itself an adjustable power lens. For example, referring to FIG. 10B, the fixed lens 1030 includes an anterior optical element 1032, a posterior optical element 1034, and a fluid chamber 1036 filled with an optical fluid and a transport substance. In operation, the first and/or second volume control elements 140 and/or 160 are exposed to a non-invasive activation energy to either decrease or increase the volume of matter in the fluid chamber 1036 and thereby adjust the optical power of the fixed lens 1030 as described above with respect to FIGS. 1-8B.


One embodiment of an oil suitable for the optical fluid 128 described above may be compounded by combining volumes of the following materials. Both equilibrium water content and refractive index can be adjusted by varying the proportions of the following components:

    • Phenylmethylcyclosiloxane. RI 1.545
    • N-(triethoxysilylpropyl)-O-Polyethylene oxide urethane, RI 1.45
    • (HYDROXYETHYLENEOXYPROPYLMETHYLSILOXANE)-(3,4-DIMETHOXYPHENYLPROPYL)METHYLSILOXANE-DIMETHYLSILOXANE TERPOLYMER, RU 1.505

Claims
  • 1. An adjustable power intraocular lens, comprising: a container having an optical component and a peripheral component extending around at least a portion of the optical component, wherein the optical component has an anterior optical element, a posterior optical element, and a fluid chamber having a chamber volume between the anterior optical element and the posterior optical element;an optical fluid in the container;a transport substance in solution with the optical fluid, wherein the transport substance is configured to pass through the container; andvolume control elements suspended in the optical fluid in the container, wherein the volume control elements are configured to be activated by a non-invasive energy and upon activation release the transport substance into the optical fluid to decrease the chamber volume and/or absorb the transport substance from the optical fluid to increase the chamber volume.
  • 2. The adjustable power intraocular lens of claim 1, wherein the volume control elements comprise only first volume control elements configured to release the transport substance into the optical fluid to decrease the chamber volume.
  • 3. The adjustable power intraocular lens of claim 1, wherein the volume control elements comprise only second volume control elements configured to absorb the transport substance from the optical fluid to increase the chamber volume.
  • 4. The adjustable power intraocular lens of claim 1, wherein the volume control elements comprise: first volume control elements configured to release the transport substance into the optical fluid to decrease the chamber volume; andsecond volume control elements configured to absorb the transport substance from the optical fluid to increase the chamber volume.
  • 5. The adjustable power intraocular lens of claim 4, wherein: the first volume control elements are activated by a first type of energy; andthe second volume control elements are active by a second type of energy different than the first type of energy.
  • 6. The adjustable power intraocular lens of claim 5, wherein: the first type of energy is selected from the group including laser energy, ultrasonic energy, electrical energy and infrared energy; andthe second type of energy is a different type of energy selected from the group including laser energy, ultrasonic energy, electrical energy and infrared energy.
  • 7. The adjustable power intraocular lens of claim 4 wherein: the first volume control elements are activated by an energy at a first wavelength or frequency; andthe second volume control elements are activated by the same type of energy at a second wavelength or frequency different than the first wavelength or frequency.
  • 8. The adjustable power intraocular lens of claim 7 wherein the energy is laser energy, the first wavelength is in a first bandwidth, and the second wavelength is in a second bandwidth outside of the first bandwidth.
  • 9. The adjustable power intraocular lens of claim 7 wherein the energy is ultrasonic energy, the first frequency is in a first frequency range, and the second frequency is in a second frequency range different that the first frequency range.
  • 10. The adjustable power intraocular lens of claim 7 wherein the energy is radiofrequency energy, the first frequency is in a first frequency range, and the second frequency is in a second frequency range different that the first frequency range.
  • 11. The adjustable power intraocular lens of claim 1 wherein the optical fluid comprises an oil and the transport substance comprises water.
  • 12. The adjustable power intraocular lens of claim 1 wherein: the peripheral component comprises an outer fluid reservoir;the optical component comprises an accommodating optical component in fluid communication with the peripheral component, and wherein the optical fluid flows between the peripheral component and the optical component in response to movement of ciliary muscles of a native eye;the volume control elements comprise (a) first volume control elements configured to release the transport substance upon activation and (b) second volume control elements configured to absorb the transport substance upon activation.
  • 13. The adjustable power intraocular lens of claim 12 wherein: the optical fluid comprises an oil;the transport substance comprises water;the first volume control elements are disrupted upon activation and release the transport substance into the optical fluid, and at least a portion of the released transport substance passes out of the container thereby decreasing a volume of matter in the fluid chamber; andthe second volume control elements are disrupted upon activation and enlarge by absorbing the transport substance from the optical fluid, and additional transport fluid from outside the container passes into the container thereby increasing the volume of matter in the fluid chamber.
  • 14. The adjustable power intraocular lens of claim 1 wherein the volume control elements comprise: first volume control elements having a shell and water contained within the shell; andsecond volume control elements having a shell and a dehydrated hydrogel within the shell.
  • 15. The adjustable power intraocular lens of claim 14 wherein the shell comprises a wax or a liposome.
CROSS-REFERENCE TO RELATED APPLICATION(S)

This application is a 35 U.S.C. § 371 U.S. National Phase application of International Patent Application No. PCT/US2018/036548, filed Jun. 7, 2018, and entitled ADJUSTABLE OPTICAL POWER INTRAOCULAR LENSES, which claims priority to U.S. Provisional Application No. 62/516,541, filed Jun. 7, 2017, and entitled ADJUSTABLE INTRAOCULAR LENS, the contents of each of the above applications are incorporated herein by reference in their entireties.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2018/036548 6/7/2018 WO 00
Publishing Document Publishing Date Country Kind
WO2018/227014 12/13/2018 WO A
US Referenced Citations (374)
Number Name Date Kind
4440918 Rice et al. Apr 1984 A
4663409 Friends et al. May 1987 A
4709996 Michelson Dec 1987 A
4731078 Stoy et al. Mar 1988 A
4731080 Galin Mar 1988 A
4842601 Smith et al. Jun 1989 A
4892543 Turley Jan 1990 A
4932966 McMaster et al. Jun 1990 A
4932971 Kelman Jun 1990 A
5074942 Orlosky et al. Dec 1991 A
5211662 Barrett et al. May 1993 A
5217491 Vanderbilt Jun 1993 A
5366502 Patel Nov 1994 A
5405386 Rheinish et al. Apr 1995 A
5423929 Grisoni et al. Jun 1995 A
5489302 Skottun Feb 1996 A
5556929 Yokoyama et al. Sep 1996 A
5612391 Chabrecek et al. Mar 1997 A
5620720 Glick et al. Apr 1997 A
5807944 Hirt et al. Sep 1998 A
5891931 Leboeuf et al. Apr 1999 A
5914355 Kuenzler Jun 1999 A
5944753 Galin et al. Aug 1999 A
5945465 Ozark et al. Aug 1999 A
5945498 Lohmann et al. Aug 1999 A
6140438 Kawaguchi et al. Oct 2000 A
6346594 Watanabe et al. Feb 2002 B1
6447920 Chabrecek et al. Sep 2002 B1
6465056 Chabrecek et al. Oct 2002 B1
6521352 Lohmann et al. Feb 2003 B1
6537316 Chambers Mar 2003 B1
6558420 Green et al. May 2003 B2
6582754 Pasic et al. Jun 2003 B1
6586038 Chabrecek et al. Jul 2003 B1
6630243 Ozark et al. Oct 2003 B2
6660035 Yaross et al. Dec 2003 B1
6685741 Landreville et al. Feb 2004 B2
6695881 Peng et al. Feb 2004 B2
6713583 Liao et al. Mar 2004 B2
6730123 Klopotek et al. May 2004 B1
6734321 Chabrecek et al. May 2004 B2
6747090 Haitjema et al. Jun 2004 B2
6761737 Ting et al. Jul 2004 B2
6764511 Ting et al. Jul 2004 B2
6767363 Green et al. Jul 2004 B1
6767979 Muir et al. Jul 2004 B1
6786934 Ting et al. Sep 2004 B2
6797004 Brady et al. Sep 2004 B1
6818017 Shu et al. Nov 2004 B1
6818158 Pham et al. Nov 2004 B2
6835410 Chabrecek et al. Dec 2004 B2
6846326 Nguyen et al. Jan 2005 B2
6858040 Ting et al. Feb 2005 B2
6884261 Zadno-Azizi et al. Apr 2005 B2
6893595 Muir et al. May 2005 B1
6893685 Pasic et al. May 2005 B2
6899732 Zadno-Azizi et al. May 2005 B2
6935743 Shadduck Aug 2005 B2
6969403 Yang et al. Nov 2005 B2
7041134 Ting et al. May 2006 B2
7087080 Ting et al. Aug 2006 B2
7097660 Portney Aug 2006 B2
7118596 Ting et al. Oct 2006 B2
7198640 Nguyen Apr 2007 B2
7217778 Flipsen et al. May 2007 B2
7226478 Ting et al. Jun 2007 B2
7300464 Tran Nov 2007 B2
7416562 Gross et al. Aug 2008 B2
7438723 Esch Oct 2008 B2
7452378 Ting et al. Nov 2008 B2
7468397 Schorzman et al. Dec 2008 B2
7479530 Chan et al. Jan 2009 B2
7557231 Schorzman et al. Jul 2009 B2
7588334 Matsushita et al. Sep 2009 B2
7591849 Richardson et al. Sep 2009 B2
7601766 Schorzman et al. Oct 2009 B2
7637947 Scholl et al. Dec 2009 B2
7714090 Iwamoto et al. May 2010 B2
7744603 Zadno-Azizi et al. Jun 2010 B2
7744646 Zadno-Azizi et al. Jun 2010 B2
7781558 Schorzman et al. Aug 2010 B2
7806929 Brown et al. Oct 2010 B2
7806930 Brown et al. Oct 2010 B2
7842087 Ben Nov 2010 B2
7883540 Niwa et al. Feb 2011 B2
7906563 Huang et al. Mar 2011 B2
7942929 Linhardt et al. May 2011 B2
8003710 Medina et al. Aug 2011 B2
8025823 Figueroa et al. Sep 2011 B2
8034107 Stenger et al. Oct 2011 B2
8048155 Shadduck et al. Nov 2011 B2
8071703 Zhou et al. Dec 2011 B2
8105623 Schorzman et al. Jan 2012 B2
8158712 Your Apr 2012 B2
8187325 Zadno-Azizi et al. May 2012 B2
8211955 Chang et al. Jul 2012 B2
8222360 Liao Jul 2012 B2
8251509 Zickler et al. Aug 2012 B2
8283429 Zhou et al. Oct 2012 B2
8328869 Burns et al. Dec 2012 B2
8357771 Medina et al. Jan 2013 B2
8377123 Zadno et al. Feb 2013 B2
8414646 Gifford et al. Apr 2013 B2
8420711 Awasthi et al. Apr 2013 B2
8425595 Evans et al. Apr 2013 B2
8425599 Shadduck et al. Apr 2013 B2
8425926 Qiu et al. Apr 2013 B2
8430928 Liao Apr 2013 B2
8454688 Evans et al. Jun 2013 B2
8486142 Bumbalough et al. Jul 2013 B2
8500806 Phillips et al. Aug 2013 B1
8585758 Woods Nov 2013 B2
8603166 Park Dec 2013 B2
8609745 Medina et al. Dec 2013 B2
8663510 Graney et al. Mar 2014 B2
8680172 Liao Mar 2014 B2
8728158 Whitsett May 2014 B2
8759414 Winter et al. Jun 2014 B2
8784485 Evans et al. Jul 2014 B2
8827447 Awasthi et al. Sep 2014 B2
8834566 Jones Sep 2014 B1
8835525 Chang et al. Sep 2014 B2
8851670 Zickler et al. Oct 2014 B2
8863749 Gooding et al. Oct 2014 B2
8877227 Ravi Nov 2014 B2
8899745 Domschke Dec 2014 B2
8900298 Chazan et al. Dec 2014 B2
8956409 Ben Feb 2015 B2
8968399 Ghabra Mar 2015 B2
8992609 Shadduck Mar 2015 B2
8993651 Chang et al. Mar 2015 B2
9005492 Chang et al. Apr 2015 B2
9005700 Qiu et al. Apr 2015 B2
9006359 Schultz et al. Apr 2015 B2
9011532 Catlin et al. Apr 2015 B2
9023915 Hu et al. May 2015 B2
9034035 Assia et al. May 2015 B2
9039174 Awasthi et al. May 2015 B2
9044302 Gooding et al. Jun 2015 B2
9052439 Samuel et al. Jun 2015 B2
9052440 Chang et al. Jun 2015 B2
9095424 Atkinson et al. Aug 2015 B2
9097840 Chang et al. Aug 2015 B2
9125736 Atkinson et al. Sep 2015 B2
9186244 Rao et al. Nov 2015 B2
9198572 Zickler et al. Dec 2015 B2
9198752 Woods Dec 2015 B2
9254189 Azar et al. Feb 2016 B2
9265604 Woods Feb 2016 B2
9280000 Simonov et al. Mar 2016 B2
9289287 Atkinson et al. Mar 2016 B2
9326848 Woods May 2016 B2
9364316 Kahook et al. Jun 2016 B1
9387069 Atkinson et al. Jul 2016 B2
9398949 Werblin Jul 2016 B2
9421088 Schieber et al. Aug 2016 B1
9427312 Tai et al. Aug 2016 B2
9456895 Shadduck et al. Oct 2016 B2
9486311 Vaughan et al. Nov 2016 B2
9498326 Tsai et al. Nov 2016 B2
9603703 Bumbalough Mar 2017 B2
9622855 Portney et al. Apr 2017 B2
9636213 Brady May 2017 B2
9655775 Boukhny et al. May 2017 B2
9681946 Kahook et al. Jun 2017 B2
9693858 Hildebrand et al. Jul 2017 B2
9744027 Jansen Aug 2017 B2
9795473 Smiley et al. Oct 2017 B2
9814568 Ben Nun Nov 2017 B2
9907881 Terrisse Mar 2018 B2
10195018 Salahieh et al. Feb 2019 B2
10350057 Argento et al. Jul 2019 B2
10526353 Silvestrini Jan 2020 B2
10548718 Salahieh et al. Feb 2020 B2
10709549 Argento et al. Jul 2020 B2
10736734 Salahieh et al. Aug 2020 B2
11065109 Argento et al. Jul 2021 B2
20010037001 Muller et al. Nov 2001 A1
20010056165 Mentak et al. Dec 2001 A1
20020072795 Green et al. Jun 2002 A1
20020086160 Qiu et al. Jul 2002 A1
20020102415 Valint, Jr. et al. Aug 2002 A1
20020103536 Landreville et al. Aug 2002 A1
20020107568 Zadno-Azizi et al. Aug 2002 A1
20020111678 Zadno-Azizi et al. Aug 2002 A1
20020116057 Ting et al. Aug 2002 A1
20020116058 Zadno-Azizi et al. Aug 2002 A1
20020116059 Zadno-Azizi et al. Aug 2002 A1
20020116060 Nguyen et al. Aug 2002 A1
20020116061 Zadno-Azizi et al. Aug 2002 A1
20020138141 Zadno-Azizi et al. Sep 2002 A1
20020173847 Pham et al. Nov 2002 A1
20020197414 Chabrecek et al. Dec 2002 A1
20030008063 Chabrecek et al. Jan 2003 A1
20030074060 Zadno-Azizi et al. Apr 2003 A1
20030074061 Pham et al. Apr 2003 A1
20030078656 Nguyen Apr 2003 A1
20030078657 Zadno-Azizi et al. Apr 2003 A1
20030078658 Zadno-Azizi Apr 2003 A1
20030100666 DeGroot et al. May 2003 A1
20030158560 Portney Aug 2003 A1
20030162929 Verbruggen et al. Aug 2003 A1
20030224185 Valint, Jr. et al. Dec 2003 A1
20040082993 Woods Apr 2004 A1
20040111152 Kelman et al. Jun 2004 A1
20040166232 Kunzler et al. Aug 2004 A1
20040169816 Esch Sep 2004 A1
20040184158 Shadduck Sep 2004 A1
20040230300 Bandhauer et al. Nov 2004 A1
20050013842 Qiu et al. Jan 2005 A1
20050049700 Zadno-Azizi et al. Mar 2005 A1
20050055092 Nguyen et al. Mar 2005 A1
20050149183 Shadduck et al. Jul 2005 A1
20050153055 Ammon et al. Jul 2005 A1
20050165410 Zadno-Azizi et al. Jul 2005 A1
20050228120 Hughes et al. Oct 2005 A1
20050228401 Zadno-Azizi et al. Oct 2005 A1
20060069432 Tran Mar 2006 A1
20060100701 Esch et al. May 2006 A1
20060100703 Evans et al. May 2006 A1
20060116765 Blake et al. Jun 2006 A1
20060178741 Zadno-Azizi et al. Aug 2006 A1
20060241752 Israel Oct 2006 A1
20060259139 Zadno-Azizi et al. Nov 2006 A1
20060271187 Zadno-Azizi et al. Nov 2006 A1
20070027540 Zadno-Azizi et al. Feb 2007 A1
20070050025 Nguyen et al. Mar 2007 A1
20070078515 Brady Apr 2007 A1
20070088433 Esch Apr 2007 A1
20070092830 Lai et al. Apr 2007 A1
20070106377 Smith et al. May 2007 A1
20070108643 Zadno-Azizi et al. May 2007 A1
20070122540 Salamone et al. May 2007 A1
20070201138 Lo et al. Aug 2007 A1
20070203317 Verbruggen et al. Aug 2007 A1
20070213817 Esch et al. Sep 2007 A1
20070232755 Matsushita et al. Oct 2007 A1
20070269488 Ravi et al. Nov 2007 A1
20080001318 Schorzman et al. Jan 2008 A1
20080003259 Salamone et al. Jan 2008 A1
20080003261 Schorzman et al. Jan 2008 A1
20080015689 Esch et al. Jan 2008 A1
20080027461 Vaquero et al. Jan 2008 A1
20080046074 Smith et al. Feb 2008 A1
20080076897 Kunzler et al. Mar 2008 A1
20080139769 Iwamoto et al. Jun 2008 A1
20080143958 Medina et al. Jun 2008 A1
20080181931 Qiu et al. Jul 2008 A1
20080234457 Zhou et al. Sep 2008 A1
20080300680 Joshua et al. Dec 2008 A1
20080314767 Lai et al. Dec 2008 A1
20090043384 Niwa et al. Feb 2009 A1
20090076603 Avery et al. Mar 2009 A1
20090118739 Kappelhof et al. May 2009 A1
20090143499 Chang et al. Jun 2009 A1
20090168012 Linhardt et al. Jul 2009 A1
20090170976 Huang et al. Jul 2009 A1
20090171459 Linhardt et al. Jul 2009 A1
20090204210 Pynson Aug 2009 A1
20090232871 Hitz et al. Sep 2009 A1
20090247661 Muller-Lierheim et al. Oct 2009 A1
20090292355 Boyd et al. Nov 2009 A1
20100016964 Werblin Jan 2010 A1
20100119744 Yokoyama et al. May 2010 A1
20100120938 Phelan et al. May 2010 A1
20100120939 Phelan et al. May 2010 A1
20100121444 Ben et al. May 2010 A1
20100160482 Nachbaur et al. Jun 2010 A1
20100179653 Argento et al. Jul 2010 A1
20100211170 Liao et al. Aug 2010 A1
20100228346 Esch et al. Sep 2010 A1
20100239633 Strome et al. Sep 2010 A1
20100324674 Brown et al. Dec 2010 A1
20110009519 Awasthi et al. Jan 2011 A1
20110046332 Breiner et al. Feb 2011 A1
20110112636 Ben Nun May 2011 A1
20110118379 Tighe et al. May 2011 A1
20110118834 Lo et al. May 2011 A1
20110133350 Qiu et al. Jun 2011 A1
20110140292 Chang et al. Jun 2011 A1
20110144228 Ravi et al. Jun 2011 A1
20110269869 Medina et al. Nov 2011 A1
20110282442 Scholl et al. Nov 2011 A1
20110295368 Betser Dec 2011 A1
20120010321 Chang et al. Jan 2012 A1
20120023869 Samuel et al. Feb 2012 A1
20120033183 Dai et al. Feb 2012 A1
20120041097 Zhou et al. Feb 2012 A1
20120046743 Pinchuk et al. Feb 2012 A1
20120063000 Batchko et al. Mar 2012 A1
20120078363 Lu Mar 2012 A1
20120078364 Stenger Mar 2012 A1
20120088843 Chang et al. Apr 2012 A1
20120088844 Kuyu et al. Apr 2012 A1
20120088861 Huang et al. Apr 2012 A1
20120115979 Chang et al. May 2012 A1
20120147323 Domschke et al. Jun 2012 A1
20120238857 Wong et al. Sep 2012 A1
20120245684 Liao et al. Sep 2012 A1
20120314183 Nakamura et al. Dec 2012 A1
20120330415 Callahan et al. Dec 2012 A1
20130013060 Zadno-Azizi et al. Jan 2013 A1
20130053954 Rao et al. Feb 2013 A1
20130095235 Bothe et al. Apr 2013 A1
20130106007 Medina et al. May 2013 A1
20130110234 DeVita et al. May 2013 A1
20130116781 Ben Nun et al. May 2013 A1
20130150961 Evans et al. Jun 2013 A1
20130176628 Batchko et al. Jul 2013 A1
20130197125 Awasthi et al. Aug 2013 A1
20130224309 Qiu et al. Aug 2013 A1
20130228943 Qiu et al. Sep 2013 A1
20130245756 Liao et al. Sep 2013 A1
20130289294 Awasthi et al. Oct 2013 A1
20130304203 Beer Nov 2013 A1
20130317607 DeBoer et al. Nov 2013 A1
20140055750 Dai et al. Feb 2014 A1
20140171539 Chang et al. Jun 2014 A1
20140171542 Chang Jun 2014 A1
20140178595 Bothe et al. Jun 2014 A1
20140180403 Silvestrini et al. Jun 2014 A1
20140180406 Simpson Jun 2014 A1
20140180407 Sohn et al. Jun 2014 A1
20140228949 Argento et al. Aug 2014 A1
20140277439 Hu et al. Sep 2014 A1
20140309735 Sohn et al. Oct 2014 A1
20140316521 McLeod et al. Oct 2014 A1
20140350124 Chang et al. Nov 2014 A1
20140379079 Ben Nun Dec 2014 A1
20150088149 Auld Mar 2015 A1
20150092155 Chang et al. Apr 2015 A1
20150105760 Silvestrini et al. Apr 2015 A1
20150152228 Chang et al. Jun 2015 A1
20150164321 Weibel et al. Jun 2015 A1
20150173892 Borja et al. Jun 2015 A1
20150177417 Goshima et al. Jun 2015 A1
20150351901 Chicevic et al. Dec 2015 A1
20160000558 Honigsbaum et al. Jan 2016 A1
20160008126 Vaughan et al. Jan 2016 A1
20160030161 Rao et al. Feb 2016 A1
20160058553 Vaughan et al. Mar 2016 A1
20160074154 Woods Mar 2016 A1
20160100938 Weeber et al. Apr 2016 A1
20160128826 Rao et al. May 2016 A1
20160151150 Sato Jun 2016 A1
20160184091 Burns et al. Jun 2016 A1
20160184092 Flaherty et al. Jun 2016 A1
20160250020 Schieber et al. Sep 2016 A1
20160256265 Borja et al. Sep 2016 A1
20160262875 Smiley et al. Sep 2016 A1
20160278914 Sato et al. Sep 2016 A1
20160296320 Humayun et al. Oct 2016 A1
20160296662 Dudic et al. Oct 2016 A1
20160317286 Rao et al. Nov 2016 A1
20160317287 Rao et al. Nov 2016 A1
20160331587 Ueno et al. Nov 2016 A1
20160361157 Honigsbaum Dec 2016 A1
20170000602 Sohn et al. Jan 2017 A1
20170020662 Shadduck Jan 2017 A1
20170049561 Smiley et al. Feb 2017 A1
20170049562 Argento et al. Feb 2017 A1
20170119521 Kahook et al. May 2017 A1
20170258581 Borja et al. Sep 2017 A1
20170348094 Sohn et al. Dec 2017 A1
20180110613 Wortz et al. Apr 2018 A1
20180161152 Argento et al. Jun 2018 A1
20180177589 Argento et al. Jun 2018 A1
20190159890 Salahieh et al. May 2019 A1
20190274823 Argento et al. Sep 2019 A1
20190290422 Ben Nun Sep 2019 A1
20190374334 Brady et al. Dec 2019 A1
20200121447 Argento et al. Apr 2020 A1
20200306031 Salahieh et al. Oct 2020 A1
20200397566 Salahieh et al. Dec 2020 A1
Foreign Referenced Citations (281)
Number Date Country
2006200142 Jul 2006 AU
2015361227 Apr 2017 AU
2010203427 May 2017 AU
2012335677 Jun 2017 AU
2015258287 Dec 2017 AU
2973684 Jul 2016 CA
2974639 Aug 2016 CA
2987311 Dec 2016 CA
2752046 Apr 2017 CA
2829143 Apr 2017 CA
1285722 Feb 2001 CN
1795090 Jun 2006 CN
101351169 Jun 2007 CN
101031257 Sep 2007 CN
101641060 Nov 2007 CN
101277659 Oct 2008 CN
101360468 Feb 2009 CN
101069106 Feb 2010 CN
102271623 Jul 2010 CN
108472129 Aug 2018 CN
101547663 Jan 2021 CN
0604369 Jun 1994 EP
0734269 Oct 1996 EP
0784652 Jul 1997 EP
0800511 Oct 1997 EP
0820601 Jan 1998 EP
0826158 Mar 1998 EP
0898972 Mar 1999 EP
0907668 Apr 1999 EP
0930357 Jul 1999 EP
0604369 Aug 1999 EP
0826158 Sep 1999 EP
0947856 Oct 1999 EP
0820601 Dec 1999 EP
0800511 Jan 2000 EP
0989138 Mar 2000 EP
1084428 Mar 2001 EP
1088246 Apr 2001 EP
1090313 Apr 2001 EP
1095711 May 2001 EP
1095965 May 2001 EP
1095966 May 2001 EP
1109853 Jun 2001 EP
0907668 Sep 2001 EP
1141054 Oct 2001 EP
1187873 Mar 2002 EP
1200019 May 2002 EP
1227773 Aug 2002 EP
1230041 Aug 2002 EP
1266246 Dec 2002 EP
0898972 Apr 2003 EP
1341485 Sep 2003 EP
1364663 Nov 2003 EP
1095711 Jan 2004 EP
1141054 Feb 2004 EP
1395302 Mar 2004 EP
1410074 Apr 2004 EP
1266246 Jun 2004 EP
1109853 Sep 2004 EP
1187873 Sep 2004 EP
1084428 Nov 2004 EP
1472305 Nov 2004 EP
1230041 Dec 2004 EP
0989138 Feb 2005 EP
1095965 Feb 2005 EP
1395302 Feb 2005 EP
1507811 Feb 2005 EP
1524953 Apr 2005 EP
1200019 Sep 2005 EP
1095966 Jan 2006 EP
1660153 May 2006 EP
1353611 Sep 2006 EP
1696975 Sep 2006 EP
1341485 Nov 2006 EP
1723933 Nov 2006 EP
1723934 Nov 2006 EP
1750157 Feb 2007 EP
1088246 Nov 2007 EP
1857477 Nov 2007 EP
1227773 Jan 2008 EP
1888660 Feb 2008 EP
1890650 Feb 2008 EP
1902737 Mar 2008 EP
1723933 Nov 2008 EP
2035050 Mar 2009 EP
2035480 Mar 2009 EP
2035486 Mar 2009 EP
1723934 Jun 2009 EP
2066732 Jun 2009 EP
2077292 Jul 2009 EP
2092376 Aug 2009 EP
1648534 Sep 2009 EP
2094193 Sep 2009 EP
2109784 Oct 2009 EP
2120789 Nov 2009 EP
2126614 Dec 2009 EP
2035480 Feb 2010 EP
2170708 Apr 2010 EP
2185589 May 2010 EP
2231207 Sep 2010 EP
1750157 Oct 2010 EP
2235094 Oct 2010 EP
2276513 Jan 2011 EP
2292672 Mar 2011 EP
2356170 Aug 2011 EP
2356497 Aug 2011 EP
2109784 Oct 2011 EP
2396355 Dec 2011 EP
2035486 Apr 2012 EP
2452212 May 2012 EP
1857477 Jun 2012 EP
1410074 Oct 2012 EP
2092376 Oct 2012 EP
2510051 Oct 2012 EP
2513711 Oct 2012 EP
2514791 Oct 2012 EP
2356170 Dec 2012 EP
2538266 Dec 2012 EP
2563275 Mar 2013 EP
2597113 May 2013 EP
2598936 Jun 2013 EP
2077292 Aug 2013 EP
2625216 Aug 2013 EP
2625217 Aug 2013 EP
2625218 Aug 2013 EP
2652532 Oct 2013 EP
1830898 Mar 2014 EP
2766750 Aug 2014 EP
2452212 Mar 2015 EP
2934383 Oct 2015 EP
2200536 Jan 2016 EP
2976042 Jan 2016 EP
3185818 Mar 2016 EP
2129331 Apr 2016 EP
3003217 Apr 2016 EP
3025678 Jun 2016 EP
2259750 Jul 2016 EP
2934383 Jul 2016 EP
3062741 Sep 2016 EP
3072476 Sep 2016 EP
1999188 Nov 2016 EP
2685935 Nov 2016 EP
2094193 Jan 2017 EP
2683287 Feb 2017 EP
3062742 Feb 2017 EP
3157466 Apr 2017 EP
3160404 May 2017 EP
3160683 May 2017 EP
3049023 Jun 2017 EP
3160683 Jun 2017 EP
3174500 Jun 2017 EP
2539351 Jul 2017 EP
2283058 Oct 2007 ES
2653325 Apr 1991 FR
59-501897 Nov 1984 JP
01-223970 Sep 1989 JP
2006-518222 Aug 2006 JP
2007-506516 Mar 2007 JP
2007-517616 Jul 2007 JP
2010-517639 May 2010 JP
2012-532685 Dec 2012 JP
2016-534816 Nov 2016 JP
9007545 Jul 1990 WO
9007575 Jul 1990 WO
9516475 Jun 1995 WO
9611235 Apr 1996 WO
9620919 Jul 1996 WO
9631791 Oct 1996 WO
9636890 Nov 1996 WO
9749740 Dec 1997 WO
9917684 Apr 1999 WO
9929818 Jun 1999 WO
9957581 Nov 1999 WO
9960428 Nov 1999 WO
9963366 Dec 1999 WO
2000004078 Jan 2000 WO
2000026980 Jun 2000 WO
2000071613 Nov 2000 WO
2001008607 Feb 2001 WO
2001030512 May 2001 WO
2001034067 May 2001 WO
2001071392 Sep 2001 WO
2002047583 Jun 2002 WO
2002094331 Nov 2002 WO
2003009014 Jan 2003 WO
2003066707 Aug 2003 WO
2003097711 Nov 2003 WO
2004010905 Feb 2004 WO
2004046768 Jun 2004 WO
2004052242 Jun 2004 WO
2004053536 Jun 2004 WO
2004054471 Jul 2004 WO
2004058318 Jul 2004 WO
2004072689 Aug 2004 WO
2005023331 Mar 2005 WO
2005065734 Jul 2005 WO
2006047383 May 2006 WO
2006103674 Oct 2006 WO
2006126095 Nov 2006 WO
2007005778 Jan 2007 WO
2007047529 Apr 2007 WO
2007047530 Apr 2007 WO
2007050394 May 2007 WO
2007064594 Jun 2007 WO
2008005644 Jan 2008 WO
2008005652 Jan 2008 WO
2008005752 Jan 2008 WO
2008024766 Feb 2008 WO
2008039655 Apr 2008 WO
2008076729 Jun 2008 WO
2008077040 Jun 2008 WO
2008082957 Jul 2008 WO
2008094876 Aug 2008 WO
2008103798 Aug 2008 WO
2008107882 Sep 2008 WO
2008116132 Sep 2008 WO
2008151088 Dec 2008 WO
2009002703 Dec 2008 WO
2020219456 Dec 2008 WO
2009015161 Jan 2009 WO
2009015226 Jan 2009 WO
2009015234 Jan 2009 WO
2009015240 Jan 2009 WO
2009085755 Jul 2009 WO
2009085756 Jul 2009 WO
2009127844 Oct 2009 WO
2010056686 May 2010 WO
2010056687 May 2010 WO
2010081093 Jul 2010 WO
2010093823 Aug 2010 WO
2011005937 Jan 2011 WO
2011026068 Mar 2011 WO
2011071790 Jun 2011 WO
2011075377 Jun 2011 WO
2011106435 Sep 2011 WO
2012006616 Jan 2012 WO
2012015639 Feb 2012 WO
2012047961 Apr 2012 WO
2012047964 Apr 2012 WO
2012047969 Apr 2012 WO
2012082704 Jun 2012 WO
2012129407 Sep 2012 WO
2021007535 Sep 2012 WO
2012129419 Apr 2013 WO
2013055746 Apr 2013 WO
2013070924 May 2013 WO
2013158942 Oct 2013 WO
2013166068 Nov 2013 WO
2014093751 Jun 2014 WO
2014093764 Jun 2014 WO
2014095690 Jun 2014 WO
2014099630 Jun 2014 WO
2014143926 Sep 2014 WO
2014149462 Sep 2014 WO
2014152017 Sep 2014 WO
2015038620 Mar 2015 WO
2015048279 Apr 2015 WO
2015066502 May 2015 WO
WO2015066532 May 2015 WO
2015148673 Oct 2015 WO
2016018932 Feb 2016 WO
2016018932 Feb 2016 WO
2016033217 Mar 2016 WO
2016038470 Mar 2016 WO
2016061233 Apr 2016 WO
2016122805 Aug 2016 WO
2016133558 Aug 2016 WO
2016140708 Sep 2016 WO
2016195095 Dec 2016 WO
2016201351 Dec 2016 WO
2013059195 May 2017 WO
2017079449 May 2017 WO
2017079733 May 2017 WO
2017087358 May 2017 WO
2009002789 Dec 2017 WO
2017208230 Dec 2017 WO
2017223544 Dec 2017 WO
2018119408 Jun 2018 WO
2017221196 Aug 2018 WO
2018222579 Dec 2018 WO
2018227014 Dec 2018 WO
Non-Patent Literature Citations (13)
Entry
Klank, et al. “CO2-laser micromachining and back-end processing for rapid production of PMMA-based microfluidic systems,” Lab Chip, 2002, 2, 242-246.
Tsao, et al. “Bonding of thermoplastic polymer microfluidics. Microfluid Nanofuild,” 2009, 6:1-16.
Umbrecht, et al. “Solvent assisted bonding of polymethylmethacrylate: characterization using the response surface methodology,” 2008, pp. 1325-1328.
Liang et al., “Bionic intraocular lens with variable focus and integrated structure,” Optical Engineering 2015, vol. 54, No. 10, Article No. 105106, Internal pp. 1-7.
International Search Report and Written Opinion for PCT Application No. PCT/US2018/036548, filed Jun. 7, 2018, Applicant: Shifamed Holdings, LLC, dated Aug. 30, 2018, 8 pages.
First Chinese Office Action dated Sep. 10, 2020 for Chinese Patent Application No. 201780087361.6, Applicant: Shifamed Holdings, LLC, filing date: Dec. 23, 2017, 11 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2020/029131, filed Apr. 21, 2020, Applicant: Shifamed Holdings, LLC, dated Sep. 21, 2020, 15 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2020/041644, filed Jul. 10, 2020, Applicant: Shifamed Holdings, LLC, dated Oct. 27, 2020, 11 pages.
European Extended Search Report dated Jan. 27, 2021 for European Patent Application No. 18809676.2, Applicant: Shifamed Holdings, LLC, filing date: May 29, 2018, 8 pages.
Chinese Office Action dated Jun. 3, 2021 for Chinese Patent Application No. 201880050631.0, Applicant: Shifamed Holdings, LLC, 7 pages.
Chinese Office Action dated Feb. 7, 2021 for Chinese Patent Application No. 201680079359.X, Applicant: Shifamed Holdings, LLC, 8 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2021/016760, filed Feb. 5, 2021, Applicant: Shifamed Holdings, LLC, dated Jun. 9, 2021, 14 pages.
Chinese Office Action dated Aug. 20, 2021 for Chinese Patent Application No. 201910547059.5, Applicant: Shifamed Holdings, LLC, 10 pages.
Related Publications (1)
Number Date Country
20200146813 A1 May 2020 US
Provisional Applications (1)
Number Date Country
62516541 Jun 2017 US